Obesity, Overweight
Conditions
Brief summary
Today's obesogenic environment, favors behavioral choices that lead to an excess of energy intake over expenditure, and consequently weight gain. Intervention strategies that harness the body's own appetite and satiety regulating signals could provide an effective means of countering excessive energy intake. The purpose of this study was to investigate whether a vegetable oil emulsion (Olibra) would result in weight loss that was associated with a reduction in food intake.
Detailed description
71 healthy subjects were enrolled (60 females, 11 males; Age: 18 - 60 years, BMI 25 - 40 kg/m2) in a two-phased, randomized, placebo-controlled, double-blind, parallel trial. During a 12-week period, Olibra was compared with a placebo (milk fat). Food intake testing was conducted on three days and anthropometric data was collected on 7 days. Key outcome measures were, body weight, body composition, energy intake, and appetite ratings.
Interventions
DIETARY_SUPPLEMENTOlibra
Fractionated palm oil and fractionated oat oil in the proportion of 95:5
OTHERPlacebo
100% milk fat
Sponsors
GNC
Pennington Biomedical Research Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy subjects of both sexes 18 - 60 years of age * body mass index (BMI) between 25 and 40 kg/m2, inclusive
Exclusion criteria
* (1) participation in another clinical trial or receipt of an investigational product 30 days prior to enrollment * (2) a dietary restraint score of \> 13 * (3) weight loss of 4.5 kg or more in the preceding three months * (4) use of tobacco products, nicotine gum or nicotine patch * (5) a medical condition or taking regular medication except oral contraceptives and hormone replacement therapy * (6) use of a nutritional product or dietary supplement or program which might interfere with the conduct of the study or place the subject at risk * (7) history of alcohol or other drug abuse in the preceding one year * (8) pregnancy, lactation, post-partum less than six months, planning a pregnancy during the study or not using an acceptable method of contraception * (9) fasting blood sugar ≥ 126 mg/dl * (10) known allergy or sensitivity to any ingredient in the supplement * (11) clinically significant deviations in normal laboratory values * (12) irregular meal-times, and * (13) unwilling to eat yogurt at test meals.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Body weight | 12 weeks | Treatment to determine if test product causes weight loss |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Body composition | 12 weeks | To determine if treatment causes a reduction in body fat mass |
| Food intake | 4 weeks | To determine if treatment results in a reduction in food intake |
Countries
United States
Outcome results
None listed